JP7505806B2 - スタビロン改変体に結合する抗体又はその抗原結合フラグメント - Google Patents

スタビロン改変体に結合する抗体又はその抗原結合フラグメント Download PDF

Info

Publication number
JP7505806B2
JP7505806B2 JP2022547007A JP2022547007A JP7505806B2 JP 7505806 B2 JP7505806 B2 JP 7505806B2 JP 2022547007 A JP2022547007 A JP 2022547007A JP 2022547007 A JP2022547007 A JP 2022547007A JP 7505806 B2 JP7505806 B2 JP 7505806B2
Authority
JP
Japan
Prior art keywords
antibody
stabilon
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022547007A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022050423A1 (https=
JPWO2022050423A5 (https=
Inventor
善和 舛廣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nihon University
Original Assignee
Nihon University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon University filed Critical Nihon University
Publication of JPWO2022050423A1 publication Critical patent/JPWO2022050423A1/ja
Publication of JPWO2022050423A5 publication Critical patent/JPWO2022050423A5/ja
Application granted granted Critical
Publication of JP7505806B2 publication Critical patent/JP7505806B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022547007A 2020-09-07 2021-09-07 スタビロン改変体に結合する抗体又はその抗原結合フラグメント Active JP7505806B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020150003 2020-09-07
JP2020150003 2020-09-07
PCT/JP2021/032827 WO2022050423A1 (ja) 2020-09-07 2021-09-07 スタビロン改変体に結合する抗体又はその抗原結合フラグメント

Publications (3)

Publication Number Publication Date
JPWO2022050423A1 JPWO2022050423A1 (https=) 2022-03-10
JPWO2022050423A5 JPWO2022050423A5 (https=) 2023-07-05
JP7505806B2 true JP7505806B2 (ja) 2024-06-25

Family

ID=80491150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022547007A Active JP7505806B2 (ja) 2020-09-07 2021-09-07 スタビロン改変体に結合する抗体又はその抗原結合フラグメント

Country Status (2)

Country Link
JP (1) JP7505806B2 (https=)
WO (1) WO2022050423A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011134226A1 (zh) 2010-04-30 2011-11-03 中兴通讯股份有限公司 一种实现多频终端频段切换的方法及装置
WO2016181836A1 (ja) 2015-05-08 2016-11-17 学校法人日本大学 標識ペプチドおよびその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5961380B2 (ja) * 2009-05-20 2016-08-02 学校法人日本大学 ペプチド、融合タンパク質、核酸、発現ベクター、形質転換体、医薬組成物、抗体タンパク質

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011134226A1 (zh) 2010-04-30 2011-11-03 中兴通讯股份有限公司 一种实现多频终端频段切换的方法及装置
WO2016181836A1 (ja) 2015-05-08 2016-11-17 学校法人日本大学 標識ペプチドおよびその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biochemical and Biophysical Research Communications，2010年，Vol.397, pp.345-349
舛廣 善和，タンパク質の高発現や安定化を可能にし、 先端医療にも有望なスタビロンタグの開発，NUBIC NEWS，日本大学産官学連携知財センター，2017年07月01日，pp.11-12

Also Published As

Publication number Publication date
JPWO2022050423A1 (https=) 2022-03-10
WO2022050423A1 (ja) 2022-03-10

Similar Documents

Publication Publication Date Title
CN113195516B (zh) 由特异性结合物识别的表位标签
WO2015067768A1 (en) High-affinity monoclonal anti-strep-tag antibody
JP2018520675A (ja) ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
CN102399288B (zh) 针对免疫球蛋白Fc段的单域重链抗体
JP7842117B2 (ja) Ｓｔｒｅｐ－ＴａｇＩＩタグに特異的に結合する抗体およびその使用
KR102453605B1 (ko) 신규 펩타이드 태그, 이에 결합하는 항체 및 이들의 용도
CN105636976A (zh) 新型肽标签以及其用途
CN117683134A (zh) 一种抗sla i纳米抗体及应用
KR101241667B1 (ko) 신규한 펩타이드 태그 및 그의 용도
JP7505806B2 (ja) スタビロン改変体に結合する抗体又はその抗原結合フラグメント
JP6574033B2 (ja) Ｗｎｔ蛋白質の製造方法および保存方法
CN113912716B (zh) 针对α-突触核蛋白抗原的抗体及其应用
CN111763255B (zh) 一种经基因修饰的vegfa蛋白及其单克隆抗体与应用
CN114317453A (zh) 一种分泌胰岛素单克隆抗体杂交瘤细胞株及其单克隆抗体与应用
KR102511816B1 (ko) c-Myc 펩타이드 특이적인 항체 및 이의 용도
EP4337679A2 (en) Mertk peptides and uses thereof
CA2991815C (en) Novel binding proteins based on di-ubiquitin muteins and methods for generation
EP4705556A2 (en) High throughput fab antibody fragment generation and ranking
JP2023178884A (ja) 膜タンパク質のＣ末端に付加したＨｉｓ－ｔａｇに対する高親和性モノクローナル抗体
KR100215391B1 (ko) 항-맥아당 결합 단백질 단일클론항체, 이를 분비하는 하이브리도마 세포주 및 그의 제조방법
JP2022060048A (ja) 抗体及びその使用
CN111733162A (zh) 一种经基因修饰的cd47蛋白及其单克隆抗体和应用
CN111705039A (zh) 一种分泌抗sox17单克隆抗体的杂交瘤细胞株及应用
Oboznaya et al. Production of monoclonal antibodies to the prion protein and their characterization
JP2018080131A (ja) Ｄｒｄ１由来のタグペプチド及びｄｒｄ１を認識する抗体

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A5211

Effective date: 20230306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240528

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240606

R150 Certificate of patent or registration of utility model

Ref document number: 7505806

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150